National Guideline Clearinghouse | The role of targeted therapies in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline.

full-text ►

National Guideline Clearinghouse | The role of targeted therapies in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline.



Congress of Neurological Surgeons

Guideline Title

The role of targeted therapies in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline.

Bibliographic Source(s)

Olson JJ, Nayak L, Ormond DR, Wen PY, Kalkanis SN, Ryken TC, AANS/CNS Joint Guidelines Committee. The role of targeted therapies in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2014 Jul;118(3):557-99. [157 references] PubMed

Guideline Status

This is the current release of the guideline.

This guideline meets NGC's 2013 (revised) inclusion criteria.

.-.-.

The role of targeted therapies in the management of progressive gli... - PubMed - NCBI

J Neurooncol. 2014 Jul;118(3):557-99. doi: 10.1007/s11060-013-1339-4. Epub 2014 Apr 17.

The role of targeted therapies in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.

Olson JJ1, Nayak L, Ormond DR, Wen PY, Kalkanis SN, Ryken TC; AANS/CNS Joint Guidelines Committee.

Author information

Abstract

QUESTION:

What is the influence of targeted medical therapies on disease control and survival in the adult patient with progressive glioblastoma?

TARGETED POPULATION:

This recommendation applies to adult patients with progressive glioblastoma

RECOMMENDATIONS:

Level III Treatment with bevacizumab is recommended as it provides improved disease control compared to historical controls as measured by best imaging response and progression free survival at 6 months. Given that there are a large number of therapies are available for progressive glioblastoma that may be applied under selected circumstances dependent on patient characteristics and treating physician judgment, it is strongly recommended that patients with progressive glioblastoma be enrolled in properly designed clinical investigations to provide convincing evidence of therapeutic value.

PMID:

 

24740195

 

[PubMed - indexed for MEDLINE]